Economy
Finance, markets, investments, cryptocurrency and economic news
Franklin Templeton's CEO warns AI threatens enterprise software companies. The industry's comfortable subscription model faces its biggest disruption yet.
Fresh wave of selling hits US software and private equity stocks, raising questions about AI investment returns and portfolio diversification strategies for global investors.
PayPal attracts takeover interest after 77% stock decline. Analyzing the fintech reshuffling and what it means for digital payments future.
PRISM by Liabooks
Place your ad in this space
[email protected]Citi's Banamex sale to Blackstone-led group signals private equity's bold move into traditional banking, reshaping Latin America's financial landscape.
Bitcoin plunged to $65,400, moving in lockstep with software ETFs as AI fears trigger broader tech selloff. The safe-haven story is officially over.
Cybersecurity stocks plummet for second day as Anthropic's AI vulnerability scanner raises fears of industry disruption. CrowdStrike down 9%, Netskope drops 10%. Is AI really threatening the $200B cybersecurity market?
Trump announces 15% tariffs worldwide, but his own Justice Department already undermined the legal authority he's now using. Court battles loom as contradictions emerge.
PRISM by Liabooks
Place your ad in this space
[email protected]AI infrastructure boom drives data centers to seek credit ratings for billions in bond funding. A new asset class emerges as traditional financing hits limits.
Russia issues 150% more work permits to Indians since invasion as both warring nations scramble for workers. Analysis of new labor migration patterns amid geopolitical conflict
As Trump signals new tariffs on Canada, Mexico, and China, investors scramble to identify which stocks will benefit and which will suffer from the trade policy shift.
Solana Company launches Pacific Backbone network connecting Seoul-Tokyo-Singapore-Hong Kong, targeting institutional demand amid crypto market downturn
PRISM by Liabooks
Place your ad in this space
[email protected]Novo Nordisk shares plunge 15% after disappointing trial results, questioning the company's obesity drug dominance. What this means for investors and the broader weight-loss market.